Hawkins Stock (NASDAQ:HWKN), Trade Ideas

Hawkins

Hawkins Inc manufactures and sells a variety of chemicals and ingredients. The firm organizes itself into three segments based on the product type. The industrial segment, which generates the majority of revenue, sells private label bleach, caustic soda, sulfuric acid, hydrochloric acid, phosphoric acid, potassium hydroxide, and aqua ammonia. The water treatment segment sells chemicals and equipment used to treat potable water, municipal and industrial wastewater, industrial process water, and non-residential swimming pool water. The health and nutrition segment sells ingredients to food, beverage, personal care, and dietary supplement producers. The vast majority of revenue comes from the United States.

HWKN

Equities

News

General

Hawkins finalizes acquisition of Industrial Research Corporation, expanding its water treatment business reach. Industrial Research supplies water treatment chemicals and equipment across Louisiana, Texas, and Arkansas. CEO Patrick H. Hawkins anticipates accelerated growth in adjacent regions.

Hawkins Splashes Into New Territory With Industrial Research Acquisition: Details

Long Ideas

Small Cap

Markets

Media

Trading Ideas

PYPL

On CNBC’s &#34;Mad Money Lightning Round,&#34; Jim Cramer recommended buying  The Allstate Corporation  (NYSE: ALL), which recently posted upbeat results for its fourth quarter.

Jim Cramer Says This Construction Giant Is &#39;So Good&#39; And &#39;Goes Higher&#39;

With Quiver Quantitative’s recent institutional holdings data, we can see that hedge funds and asset managers have been increasing their holdings in Hawkins Inc. (NASDAQ: HWKN).

The Bull Case for Hawkins Inc. (NASDAQ: HWKN)

Hawkins Inc

Specialty chemical company&nbsp;Hawkins Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HWKN#NASDAQ">HWKN</a>) has completed the&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/03/g37584919/hawkins-inc-expands-water-treatment-footprint-with-acquisition-of-industrial-research-corporation" rel="noreferrer noopener">acquisition of&nbsp;Industrial Research Corporation.</a>&nbsp;
Industrial Research distributes water treatment chemicals and equipment to its customers in central to northern Louisiana, eastern Texas, and southern Arkansas. The financial and other details of the transaction were not disclosed.
&#8220;As we continue to execute on our strategy to grow our water treatment business, we believe this tuck-in acquisition fills a geographical void in northern Louisiana and east Texas and will allow us to accelerate our growth in the surrounding regions,&#8221; said CEO Patrick H. Hawkins.
Hawkins held $5.7 million in <a href="https://www.benzinga.com/pressreleases/24/01/g36876461/hawkins-inc-reports-third-quarter-fiscal-2024-results" target="_blank" rel="noreferrer noopener">cash and equivalents as of December 31, 2023</a>.
Hawkins formulates, distributes, blends, and manufactures products for its Industrial, Water Treatment, and Health &amp; Nutrition customers.
Price Action: HWKN shares are trading higher by 3.07% at $71.57 on the last check Monday.

Hawkins, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HWKN#NASDAQ">HWKN</a>), a leading specialty chemical and ingredients company, has completed the acquisition of Industrial Research Corporation. Industrial Research distributes water treatment chemicals and equipment for its customers in central to northern Louisiana, eastern Texas and southern Arkansas.
"As we continue to execute on our strategy to grow our water treatment business, we believe this tuck-in acquisition fills a geographical void in northern Louisiana and east Texas and will allow us to accelerate our growth in the surrounding regions. Industrial Research has built a strong business that is well-connected with the local community and we intend to maintain those connections. I would like to welcome the Industrial Research team to the Hawkins organization and look forward to our continued growth together," said Hawkins Chief Executive Officer Patrick H. Hawkins.

Hawkins Expands Water Treatment Footprint With Acquisition Of Industrial Research Corporation; No Financial Terms Disclosed

On CNBC&rsquo;s &quot;Mad Money Lightning Round,&quot; Jim Cramer recommended buying The Allstate Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/all#NYSE">ALL</a>), which recently posted upbeat <a href="https://www.benzinga.com/insights/earnings/24/02/36992969/allstate-q4-earnings-insights">results for its fourth quarter</a>.
Cramer&#39;s advice comes as Allstate &mdash; one of the largest insurance companies in the country&nbsp;&mdash; decided to stop offering new policies <a href="https://www.benzinga.com/news/24/02/36966167/deadly-floods-in-california-puts-38-million-under-emergency-alert-while-state-faces-massive-insuranc">in California</a>, which has been <a href="https://www.benzinga.com/markets/equities/23/09/34211910/home-insurance-shockwave-climate-risks-trigger-coverage-cuts-as-claims-surge-report">battered by wildfires in recent years</a>.
Kimberly-Clark Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/kmb#NYSE">KMB</a>) didn&rsquo;t report great quarterly numbers, Cramer said. &quot;I think the company is in the midst of a turn, but it&rsquo;s not going as quickly as I&rsquo;d like.&quot;
Kimberly-Clark said fourth-quarter sales remained flat year-over-year at $4.97 billion, missing the consensus estimate of $4.98 billion.
When asked about PayPal Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pypl#NASDAQ">PYPL</a>), Cramer said, &quot;You should be worried.&quot;
PayPal reported upbeat earnings and sales results for its fourth quarter. However, the company said it expects full-year 2024 adjusted earnings to be in line with full-year 2023 earnings of $5.10 per share.
Lennar Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/len#NYSE">LEN</a>) is &quot;so good,&quot; Cramer said. &quot;Lennar goes higher.&quot;
Lennar&rsquo;s board recently increased its annual dividend to $2.00 from $1.50 per share. The move will result in a quarterly cash dividend of $0.50 per share for both Class A and Class B common stock. The dividend is payable on Feb. 7, 2024, to holders of record at the close of <a href="https://www.benzinga.com/markets/equities/24/01/36571430/homebuilder-lennars-aggressive-capital-return-strategy-higher-dividends-and-massive-stock-buybac">business on Jan. 24, 2024</a>.
Don&rsquo;t forget to check out our <a href="https://www.benzinga.com/premarket/"> premarket coverage here </a> 
When asked about Hawkins (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hwkn#NASDAQ">HWKN</a>), he said, &quot;I think the stock is a buy.&quot;
Hawkins recently reported worse-than-expected third-quarter revenue results.
<h3>Price Action:</h3>
<ul>
<li>Shares of Lennar fell 0.2% to close at $153.02 on Friday.</li>
<li>Hawkins shares rose 2.7% to $63.07 on Friday.</li>
<li>PayPal shares rose 5% to settle at $58.91 during Friday&rsquo;s session.</li>
<li>Shares of Kimberly-Clark fell 0.4% to close at $119.81 on Friday.</li>
<li>Allstate shares fell 1.1% to settle at $160.03 on Friday.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/02/37032577/top-5-health-care-stocks-that-are-preparing-to-pump-in-february"> Top 5 Health Care Stocks That Are Preparing To Pump In February </a> 
Image: Shutterstock

Jim Cramer Says This Construction Giant Is 'So Good' And 'Goes Higher'

WIIM

Hawkins shares are trading lower after the company reported worse-than-expected Q3 revenue results.

Hawkins (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HWKN#NASDAQ">HWKN</a>) reported its Q3 earnings results on Wednesday, January 31, 2024 at 04:10 PM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Hawkins beat estimated earnings by 16.39%, reporting an EPS of $0.71 versus an estimate of $0.61.
Revenue was down $10.72 million from the same period last year.
<h3>Past Earnings Performance</h3>
Last quarter the company beat on EPS by $0.1 which was followed by a 5.03% drop in the share price the next day.

To track all earnings releases for Hawkins <a href="https://www.benzinga.com/quote/HWKN/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

Recap: Hawkins Q3 Earnings

Hawkins (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HWKN#NASDAQ">HWKN</a>) reported quarterly earnings of $0.71 per share which beat the analyst consensus estimate of $0.61 by 16.39 percent. This is a 39.22 percent increase over earnings of $0.51 per share from the same period last year. The company reported quarterly sales of $208.50 million which missed the analyst consensus estimate of $221.24 million by 5.76 percent. This is a 4.89 percent decrease over sales of $219.22 million the same period last year.

Hawkins Q3 EPS $0.71 Beats $0.61 Estimate, Sales $208.50M Miss $221.24M Estimate

<h3>Companies Reporting Before The Bell</h3>
&bull; Novartis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) is likely to report quarterly earnings at $1.68 per share on revenue of $11.56 billion.
&bull; Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) is likely to report quarterly earnings at $0.65 per share on revenue of $8.82 billion.
&bull; Regis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGS#NASDAQ">RGS</a>) is likely to report quarterly loss at $1.19 per share on revenue of $52.94 million.
&bull; Boeing (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) is projected to report quarterly loss at $0.74 per share on revenue of $21.12 billion.
&bull; Hess (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HES#NYSE">HES</a>) is likely to report quarterly earnings at $1.47 per share on revenue of $2.60 billion.
&bull; Lennox Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LII#NYSE">LII</a>) is expected to report quarterly earnings at $3.48 per share on revenue of $1.14 billion.
&bull; Nasdaq (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDAQ#NASDAQ">NDAQ</a>) is estimated to report quarterly earnings at $0.70 per share on revenue of $1.03 billion.
&bull; Evercore (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVR#NYSE">EVR</a>) is expected to report quarterly earnings at $1.66 per share on revenue of $715.79 million.
&bull; Aptiv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APTV#NYSE">APTV</a>) is estimated to report quarterly earnings at $1.32 per share on revenue of $5.04 billion.
&bull; Brinker International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EAT#NYSE">EAT</a>) is expected to report quarterly earnings at $0.96 per share on revenue of $1.08 billion.
&bull; Cencora (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>) is likely to report earnings for its first quarter.
&bull; CGI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GIB#NYSE">GIB</a>) is likely to report quarterly earnings at $1.36 per share on revenue of $2.68 billion.
&bull; Mastercard (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>) is likely to report quarterly earnings at $3.08 per share on revenue of $6.48 billion.
&bull; Avnet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVT#NASDAQ">AVT</a>) is likely to report quarterly earnings at $1.40 per share on revenue of $6.17 billion.
&bull; Hess Midstream (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HESM#NYSE">HESM</a>) is projected to report quarterly earnings at $0.63 per share on revenue of $357.92 million.
&bull; M/I Homes (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MHO#NYSE">MHO</a>) is estimated to report quarterly earnings at $4.94 per share on revenue of $1.19 billion.
&bull; Fortive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FTV#NYSE">FTV</a>) is estimated to report quarterly earnings at $0.94 per share on revenue of $1.56 billion.
&bull; Radcom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDCM#NASDAQ">RDCM</a>) is projected to report quarterly earnings at $0.15 per share on revenue of $13.55 million.
&bull; Silicon Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLAB#NASDAQ">SLAB</a>) is likely to report quarterly loss at $1.43 per share on revenue of $85.16 million.
&bull; Old Dominion Freight Line (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODFL#NASDAQ">ODFL</a>) is likely to report quarterly earnings at $2.85 per share on revenue of $1.50 billion.
&bull; Rockwell Automation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROK#NYSE">ROK</a>) is projected to report quarterly earnings at $2.63 per share on revenue of $2.10 billion.
&bull; Automatic Data Processing (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADP#NASDAQ">ADP</a>) is projected to report quarterly earnings at $2.10 per share on revenue of $4.66 billion.
&bull; Silgan Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLGN#NYSE">SLGN</a>) is projected to report quarterly earnings at $0.58 per share on revenue of $1.39 billion.
&bull; Columbus McKinnon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCO#NASDAQ">CMCO</a>) is projected to report quarterly earnings at $0.68 per share on revenue of $250.34 million.
&bull; Group 1 Automotive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPI#NYSE">GPI</a>) is estimated to report quarterly earnings at $10.48 per share on revenue of $4.41 billion.
&bull; Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) is expected to report quarterly earnings at $5.64 per share on revenue of $10.73 billion.
&bull; GSK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) is likely to report quarterly earnings at $0.75 per share on revenue of $9.61 billion.
&bull; Nomura Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NMR#NYSE">NMR</a>) is projected to report earnings for its third quarter.
&bull; Extreme Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXTR#NASDAQ">EXTR</a>) is expected to report quarterly earnings at $0.25 per share on revenue of $295.61 million.
&bull; New York Community (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NYCB#NYSE">NYCB</a>) is expected to report quarterly earnings at $0.28 per share on revenue of $803.17 million.
&bull; Phillips 66 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSX#NYSE">PSX</a>) is likely to report quarterly earnings at $2.34 per share on revenue of $36.29 billion.
&bull; Teva Pharmaceutical Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) is projected to report quarterly earnings at $0.76 per share on revenue of $4.01 billion.
&bull; Roper Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROP#NASDAQ">ROP</a>) is expected to report quarterly earnings at $4.34 per share on revenue of $1.58 billion.
&bull; Avery Dennison (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVY#NYSE">AVY</a>) is projected to report quarterly earnings at $2.16 per share on revenue of $2.09 billion.
&bull; MarketAxess Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MKTX#NASDAQ">MKTX</a>) is projected to report quarterly earnings at $1.73 per share on revenue of $195.93 million.
&bull; Otis Worldwide (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OTIS#NYSE">OTIS</a>) is estimated to report quarterly earnings at $0.86 per share on revenue of $3.57 billion.
&bull; Navient (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAVI#NASDAQ">NAVI</a>) is likely to report quarterly earnings at $0.75 per share on revenue of $201.17 million.
&bull; Central Pacific Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPF#NYSE">CPF</a>) is estimated to report quarterly earnings at $0.48 per share on revenue of $50.78 million.
&bull; Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) is estimated to report quarterly earnings at $0.51 per share on revenue of $3.59 billion.
&bull; Banco Santander (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAN#NYSE">SAN</a>) is estimated to report earnings for its fourth quarter.
&bull; United Microelectronics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UMC#NYSE">UMC</a>) is likely to report quarterly earnings at $0.15 per share on revenue of $1.70 billion.
<h3>Companies Reporting After The Bell</h3>
&bull; Keysight Techs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KEYS#NYSE">KEYS</a>) is projected to report earnings for its first quarter.
&bull; EZCORP (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EZPW#NASDAQ">EZPW</a>) is estimated to report quarterly earnings at $0.29 per share on revenue of $296.28 million.
&bull; Markel Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MKL#NYSE">MKL</a>) is estimated to report quarterly earnings at $21.36 per share on revenue of $3.76 billion.
&bull; John B Sanfilippo &amp; Son (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBSS#NASDAQ">JBSS</a>) is estimated to report earnings for its second quarter.
&bull; Unifi (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UFI#NYSE">UFI</a>) is likely to report quarterly loss at $0.85 per share on revenue of $135.57 million.
&bull; Credit Acceptance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CACC#NASDAQ">CACC</a>) is expected to report quarterly earnings at $5.99 per share on revenue of $460.96 million.
&bull; SEI Inv (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEIC#NASDAQ">SEIC</a>) is projected to report quarterly earnings at $0.92 per share on revenue of $479.93 million.
&bull; Good Times Restaurants (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTIM#NASDAQ">GTIM</a>) is estimated to report earnings for its first quarter.
&bull; Selective Insurance Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIGI#NASDAQ">SIGI</a>) is estimated to report quarterly earnings at $1.94 per share on revenue of $958.13 million.
&bull; Hanover Insurance Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THG#NYSE">THG</a>) is expected to report quarterly earnings at $2.73 per share on revenue of $1.41 billion.
&bull; Brandywine Realty Tr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDN#NYSE">BDN</a>) is estimated to report quarterly loss at $0.07 per share on revenue of $135.47 million.
&bull; DLH Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLHC#NASDAQ">DLHC</a>) is likely to report quarterly earnings at $0.12 per share on revenue of $101.00 million.
&bull; AvalonBay Communities (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVB#NYSE">AVB</a>) is estimated to report quarterly earnings at $1.34 per share on revenue of $701.24 million.
&bull; Boot Barn Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOOT#NYSE">BOOT</a>) is likely to report quarterly earnings at $1.77 per share on revenue of $521.22 million.
&bull; C.H. Robinson Worldwide (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRW#NASDAQ">CHRW</a>) is projected to report quarterly earnings at $0.81 per share on revenue of $4.34 billion.
&bull; 8x8 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EGHT#NASDAQ">EGHT</a>) is estimated to report quarterly earnings at $0.10 per share on revenue of $183.49 million.
&bull; Axis Capital Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXS#NYSE">AXS</a>) is estimated to report quarterly earnings at $1.08 per share on revenue of $1.23 billion.
&bull; Hawkins (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HWKN#NASDAQ">HWKN</a>) is projected to report quarterly earnings at $0.61 per share on revenue of $221.24 million.
&bull; Accuray (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARAY#NASDAQ">ARAY</a>) is projected to report quarterly loss at $0.05 per share on revenue of $106.67 million.
&bull; Wolfspeed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOLF#NYSE">WOLF</a>) is likely to report quarterly loss at $0.66 per share on revenue of $206.25 million.
&bull; Kulicke &amp; Soffa Indus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLIC#NASDAQ">KLIC</a>) is projected to report quarterly earnings at $0.26 per share on revenue of $172.01 million.
&bull; MaxLinear (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MXL#NASDAQ">MXL</a>) is expected to report quarterly earnings at $0.01 per share on revenue of $125.11 million.
&bull; Flex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLEX#NASDAQ">FLEX</a>) is likely to report quarterly earnings at $0.61 per share on revenue of $6.73 billion.
&bull; Aflac (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AFL#NYSE">AFL</a>) is likely to report quarterly earnings at $1.45 per share on revenue of $4.40 billion.
&bull; Century Communities (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCS#NYSE">CCS</a>) is expected to report quarterly earnings at $2.28 per share on revenue of $896.79 million.
&bull; Digi Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DGII#NASDAQ">DGII</a>) is expected to report quarterly earnings at $0.44 per share on revenue of $105.61 million.
&bull; Qualcomm (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>) is estimated to report quarterly earnings at $2.37 per share on revenue of $9.51 billion.
&bull; BrightView Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BV#NYSE">BV</a>) is likely to report quarterly earnings at $0.04 per share on revenue of $645.09 million.
&bull; Qorvo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QRVO#NASDAQ">QRVO</a>) is projected to report quarterly earnings at $1.66 per share on revenue of $1.00 billion.
&bull; UGI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UGI#NYSE">UGI</a>) is estimated to report quarterly earnings at $1.05 per share on revenue of $2.67 billion.
&bull; MagnaChip Semiconductor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MX#NYSE">MX</a>) is likely to report quarterly loss at $0.26 per share on revenue of $52.47 million.
&bull; Core Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLB#NYSE">CLB</a>) is likely to report quarterly earnings at $0.19 per share on revenue of $127.92 million.
&bull; Meritage Homes (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTH#NYSE">MTH</a>) is likely to report quarterly earnings at $5.17 per share on revenue of $1.53 billion.
&bull; Corteva (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTVA#NYSE">CTVA</a>) is projected to report quarterly earnings at $0.06 per share on revenue of $3.62 billion.
&bull; MetLife (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MET#NYSE">MET</a>) is expected to report quarterly earnings at $1.90 per share on revenue of $18.46 billion.
&bull; Landstar System (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSTR#NASDAQ">LSTR</a>) is expected to report quarterly earnings at $1.62 per share on revenue of $1.24 billion.
&bull; Rayonier (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RYN#NYSE">RYN</a>) is projected to report quarterly earnings at $0.15 per share on revenue of $229.75 million.
&bull; MGIC Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTG#NYSE">MTG</a>) is expected to report quarterly earnings at $0.57 per share on revenue of $292.72 million.
&bull; NEXTracker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXT#NASDAQ">NXT</a>) is estimated to report quarterly earnings at $0.48 per share on revenue of $619.23 million.
&bull; Conmed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNMD#NYSE">CNMD</a>) is estimated to report quarterly earnings at $1.11 per share on revenue of $332.20 million.
&bull; Landmark Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LARK#NASDAQ">LARK</a>) is likely to report earnings for its fourth quarter.
&bull; PTC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTC#NASDAQ">PTC</a>) is expected to report quarterly earnings at $0.96 per share on revenue of $538.63 million.
&bull; Align Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>) is expected to report quarterly earnings at $2.16 per share on revenue of $931.35 million.
&bull; Vista Outdoor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VSTO#NYSE">VSTO</a>) is estimated to report quarterly earnings at $0.81 per share on revenue of $687.67 million.
&bull; Tetra Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTEK#NASDAQ">TTEK</a>) is likely to report quarterly earnings at $1.34 per share on revenue of $990.66 million.
&bull; Benchmark Electronics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHE#NYSE">BHE</a>) is projected to report quarterly earnings at $0.56 per share on revenue of $707.50 million.
&bull; NewMarket (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEU#NYSE">NEU</a>) is likely to report earnings for its fourth quarter.
&bull; Cimpress (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPR#NASDAQ">CMPR</a>) is expected to report quarterly earnings at $1.24 per share on revenue of $892.10 million.
This article was generated by Benzinga&#39;s automated content engine and reviewed by an editor.

ALGN

APTV

ARAY

BOOT

CACC

CHRW

CMCO

CMPR

CNMD

CTVA

DGII

DLHC

EGHT

EXTR

EZPW

FLEX

GTIM

HESM

JBSS

KEYS

KLIC

LARK

LSTR

MKTX

NAVI

NDAQ

NYCB

ODFL

OTIS

QCOM

QRVO

RDCM

SEIC

SIGI

SLAB

SLGN

TEVA

TTEK

VSTO

WOLF

Earnings Scheduled For January 31, 2024

Hawkins (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HWKN#NASDAQ">HWKN</a>) is set to give its latest quarterly earnings report on Wednesday, 2024-01-31. Here's what investors need to know before the announcement.
Analysts estimate that Hawkins will report an earnings per share (EPS) of $0.61. 
Hawkins bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Historical Earnings Performance</h3>
Last quarter the company beat EPS by $0.10, which was followed by a 5.03% drop in the share price the next day.
Here's a look at Hawkins's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1</td>
<td>0.61</td>
<td></td>
<td>0.49</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.1</td>
<td>1.12</td>
<td>0.55</td>
<td>0.51</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-5.03%</td>
<td>8.02%</td>
<td>10.57%</td>
<td>7.21%</td>
</tr>
</tbody>
</table>

<h3>Stock Performance</h3>
Shares of Hawkins were trading at $68.0 as of January 29. Over the last 52-week period, shares are up 70.11%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. 
<a href="https://www.benzinga.com/quote/HWKN/earnings">To track all earnings releases for Hawkins visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Preview Of Hawkins's Earnings

With&nbsp;Quiver Quantitative&rsquo;s recent&nbsp;institutional holdings data, we can see that hedge funds and asset managers have been increasing their holdings in Hawkins Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hwkn#NASDAQ">HWKN</a>). Firms such as Charles Schwab Investment Management, Citadel Advisors, and Renaissance Technologies have all recently added to their HWKN positions. Most notably, Charles Schwab Investment Management increased shares held by 2.37% (as filed on 9/30), bringing their total HWKN holdings to 233,193 shares worth around $16.4 million dollars at current market prices. With this in mind, we took a closer look at some of the reasons why many investors may be bullish on Hawkins Inc.
In November, Hawkins Inc. reported earnings results for the second quarter of FY24. During the quarter, Hawkins reported record quarterly gross profit of $53.9 million dollars (16% YoY increase), which contributed to a record quarterly operating income (EBIT) of $33 million dollars (25% YoY increase). YTD diluted EPS was recorded at $2.22/share, growing 24% over the prior year. Additionally, the business added six water treatment facilities (a business segment they have been focused on growing), via the acquisitions of Water Solutions Unlimited and The Miami Products &amp; Chemical Company. CEO and President Patrick H. Hawkins had this to say about the quarter, &quot;We are pleased with our strong year-over-year performance in the second quarter, with our bottom line growing 29%, following our strong first-quarter growth of 19%. Our Water Treatment group once again led the way with revenue growth of 17% and operating income growth of nearly 70%. We continue to see profit growth within this segment, as we execute on our strategy to grow both the legacy business and the businesses we have acquired over the last few years. Although our Industrial group sales declined year-over-year, operating income was up 2%. In addition, the year-over-year second quarter sales decline in our Health and Nutrition group slowed to about half of what it was in the first quarter, showing signs of improvement.&quot; With these earnings results in mind, we believe that Hawkins Inc. is a compelling investment opportunity trading at an attractive valuation.&nbsp;
Hawkins Inc. is a leading specialty chemical and ingredients company, renowned for its expertise in formulating, distributing, blending, and manufacturing a wide range of products for diverse sectors including Industrial, Water Treatment, and Health and Nutrition. The company generates revenue through its three primary segments: the Industrial Segment, which provides a variety of chemicals and services to industries such as agriculture and pharmaceuticals; the Water Treatment Segment, specializing in chemicals and solutions for water treatment needs; and the Health and Nutrition Segment, offering ingredient solutions to manufacturers in the food, health, and wellness sectors. Hawkins Inc. is distinguished by its specialized sales staff, quality products, and comprehensive services, positioning itself as a vital player in its served markets, with a strong presence primarily in the central United States and national distribution for certain products.
Hawkins Inc. operates in a highly competitive specialty chemicals and ingredients industry, where it contends with numerous producers, distributors, and sales agents. Despite the presence of larger competitors, Hawkins differentiates itself by providing quality products, outstanding customer service, and value-added services, including product formulation, to maintain a competitive edge. The company relies on a broad network of suppliers, including major chemical producers in the United States and a variety of domestic and international vendors for health and nutrition ingredients. Hawkins maintains robust relationships through distributorship agreements and supply contracts, ensuring a consistent supply of raw materials, though the availability of these materials is subject to market dynamics. The company&#39;s ability to leverage long-standing supplier relationships helps in navigating supply chain challenges, securing competitive pricing, and maintaining product availability, even when supplies are limited.
Management is solid, and their capital allocation priorities do a great job of creating long-term shareholder value. Hawkins&rsquo; Board of Directors previously authorized up to 2.6 million shares of common stock to be repurchased in the open market or in privately negotiated transactions. In FY21, FY22, and FY23, management repurchased 166,088, 240,501, and 181,657 shares of common stock, respectively. As of April, there remained 1,129,348 authorized shares for further share repurchases. Management largely uses these repurchases to offset the dilutive effects of share-based compensation, ensuring that shareholders aren&rsquo;t diluted. In addition to share repurchases, Hawkins also offers dividends. In fact, the business has 38 years of continued dividend growth. Usually, we don&rsquo;t like to see compounding businesses like Hawkins pay out dividends, as these dividend payments often take away from earnings that could be used for reinvestments into the business&rsquo; growth. However, with a payout ratio of only 18.3% (meaning that Hawkins pays outs 18.3% of net income to shareholders in the form of dividends), the business has plenty of additional earnings capacity (81.7% of net income) to use for reinvestments, debt pay downs, and other business needs. As we can see, management&rsquo;s repurchase of common shares to reverse the dilutive effect of share-based compensation and long-term dividend growth (while keeping the dividend payout ratio low) do a great job of creating long-term shareholder value, while also allowing for a large chunk of earnings to be reinvested back into the business.
In terms of management incentives, management is incentivized well, with a compensation structure that does a great job of aligning shareholder and management interests, while also doing a great job of retaining executive talent over the long term. The compensation structure includes a base salary, annual non-equity compensation, and annual equity rewards. The annual non-equity compensation awards NEOs based on predetermined performance threshold benchmarks. In FY23, these performance thresholds were based on EBT (earnings before income tax) and an industrial group operational performance measure. One unique characteristic of this bonus is that 80% of the threshold must be met at a minimum to receive any of the annual cash incentive payment. Therefore, these thresholds are almost always met, and often exceed 100% of the target threshold (showing how incentives lead to outcomes). The annual equity award is paid out via PRSUs (performance-based restricted stock units) that vest over two years. As we can see, the annual equity incentives do a great job of aligning shareholder and management interests, while also retaining executive talent. With a large part of their salary coming from equity rewards, management is incentivized to maximize total shareholder return, much to the delight of passive shareholders. Additionally, with these rewards being vested over time, management is incentivized to stay on board. It&rsquo;s hard to grow a business over the long-term if management is a revolving door.
Hawkins is a very efficient business. The business currently operates at a LTM ROE of 19.3% and a ROIC of 20.2%. With the business operating at a WACC of 8.2%, Hawkins currently operates at a ROIC to WACC ratio of around 2.5x, showcasing the business&rsquo; ability to generate returns on capital far greater than the business&rsquo; weighted average cost of capital. Businesses that are able to generate high returns on capital are referred to as compounders, businesses that are able to rapidly compound earnings and intrinsic value over the long-term, handsomely rewarding shareholders in the process. Going back to ROE, return on equity is a great way to measure a company&rsquo;s ability to generate shareholder value. Increasing ROE over time may suggest that a business is reinvesting its earnings wisely, so as to increase productivity and profitability. Since 2016, Hawkins has expanded ROE from 9.3% (ROE = Net Income / Shareholders&rsquo; Equity) to 19.3% today. Looking further, we can see some solid growth in EBIT within the last decade (largely due to strong top-line revenue growth and incrementally expanding EBIT margins). EBIT is a great way to measure the profitability of a business&rsquo; core operations. Since 2014, Hawkins has grown EBIT at a CAGR of 11.8%, with EBIT margins incrementally expanding from 8% of revenue in 2014 to 10.3% of revenue today.
Analyzing Hawkins&rsquo; income statement, we can see some stellar sustained growth in revenue, gross profit, and earnings within the last decade. Since 2014, Hawkins has grown revenue at a CAGR of 10.4%, with gross profit also growing at a CAGR of around 10.4% in that same time frame (gross profit margins have stayed relatively flat over the last decade, usually hovering around 17 - 20% of revenue). In terms of earnings, Hawkins has grown EBITDA at a CAGR of 10.8% since 2014, while EPS has grown 12.8% in that same time frame. This growth in EPS can somewhat be attributed to small share repurchases over the last decade. Since 2014, shares outstanding have decreased 1.4%, just enough to offset dilutive practices like share based compensation for management and other employees. It must be noted that Hawkins has a low float, with only 20.94 million shares outstanding (please note that float and shares outstanding are similar yet different concepts, where float is the number of shares available for trading by the general public).
Looking at Hawkins&rsquo; balance sheet, we can see that the business operates in solid financial health. The business currently holds nearly $11 million dollars worth of cash and equivalents on the balance sheet, with around $50 million dollars of long-term debt. The business currently operates at a net debt of around $58 million dollars, signifying a Net Debt/EBITDA of around 0.45x. Therefore, theoretically, the business could pay off its debt in less than half a year with its current EBITDA (and this ratio will only go lower, assuming that EBITDA continues to grow at the rate it has over the last decade, and the business keeps debt to a minimum). As we can see, the business has plenty of runway to pay off its debt obligations, with the business operating with little debt. Low debt is a great quality for a small compounding stock like Hawkins to have. With low debt, Hawkins can focus on initiatives that drive long-term shareholder value. These initiatives include reinvestments back into the business at high rates of return, share repurchases, and dividends (which can include increasing or offering a dividend).
Analyzing Hawkins&rsquo; cash flow statement, we can see stellar sustained growth in net income and free cash flow within the last decade, showcasing the business&rsquo; improved operational efficiency over that time period. Since 2014, net income has grown at a CAGR of 12.7%, with free cash flow growing at a CAGR of 15.3% in that same time period (calculated using 2014 FCF and LTM FCF). Hawkins, over the last decade, has had shaky free cash flow generation at best, however, that can be explained by how FCF is calculated (Operating Cash Flow - Capex) and Hawkin&rsquo;s business model. Capital expenditures have risen heavily over time ($20.8 million in FY21, $28.5 million in FY22, $48.3 million in FY23, and projected capital expenditures of $40-$45 million in FY24). These capital expenditures are being used for growth in the business, specifically being used for investments into facility improvements and expansion, new trucks, safety equipment, and other additions of PP&amp;E. This is great, as these capital expenditures will pay dividends in the future, however, at the moment, they hurt free cash flow generation. At the surface level, this may be a concern to investors, however, over time, we believe that free cash flow will stabilize as Capex stabilizes, and these current capital expenditures will help grow the business, leading to top-line revenue growth and higher cash flows. This is a great example of why you need to dig deep into the financials of a business to understand things like profitability and cash flow generation. A great example of this is Amazon. For years, Amazon was an unprofitable enterprise, however, this was only because of large R&amp;D expenses that crippled EBIT and net income. On the surface level, an investor may think that Amazon is a bad business. However, these R&amp;D expenses paid dividends, allowing Amazon to introduce new products and improve the customer experience, leading to strong top-line revenue growth and cash flow growth over time.
After conducting a reverse discounted cash flow analysis, we can see that Hawkins is trading at share prices that imply a -1.85% growth rate (CAGR) in free cash flow over the next decade, using a perpetuity growth rate of 3% (largely in line with US GDP growth) and a discount rate of 8.2% (Hawkins&rsquo; WACC). Hawkins&rsquo; is a high quality business, and despite the shaky free cash flow generation described above, we believe that this valuation is very cheap. Large capital expenditures have depressed free cash flow generation over the past few years, however, as the business grows and capex stabilizes (which we believe is evidenced by their FY24 Capex projections), we believe that Hawkins&rsquo; can turn into a cash generating machine that can continue to reinvest cash back into the business as the business continues to compound, leading to further cash flow generation. The price implied expectations of investors seem to be very low, and rightfully so given the business&rsquo; current free cash flow generation situation. However, over time, we believe that top-line growth due to current capital expenditures will drive increased free cash flow generation, making these current price implied expectations seem very cheap in hindsight. We believe a 5% free cash flow growth rate (CAGR) is a fair value for the business, which gives us an implied share price of $112.44/share and an implied return of nearly 60%. These valuations are based entirely on our proprietary models, and we encourage all investors to do their own due diligence when it comes to valuation, as it may lead to you a completely different viewpoint on the business.
Keep an eye out for&nbsp;HWKN stock&rsquo;s latest news, data, and more with&nbsp;<a href="https://www.quiverquant.com/">Quiver Quantitative</a>.&nbsp;
This article is from an external contributor. It does not represent Benzinga's reporting and has not been edited for content or accuracy.

BWS Financial analyst Hamed Khorsand maintains Hawkins (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HWKN#NASDAQ">HWKN</a>) with a Buy and raises the price target from $62 to $74.

Price Target

Analyst Ratings

BWS Financial Maintains Buy on Hawkins, Raises Price Target to $74

Hawkins (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HWKN#NASDAQ">HWKN</a>) reported quarterly earnings of $1.10 per share which beat the analyst consensus estimate of $1.00 by 10 percent. This is a 27.91 percent increase over earnings of $0.86 per share from the same period last year. The company reported quarterly sales of $236.53 million which missed the analyst consensus estimate of $250.24 million by 5.48 percent. This is a 1.93 percent decrease over sales of $241.19 million the same period last year.

Hawkins Q2 EPS $1.10 Beats $1.00 Estimate, Sales $236.53M Miss $250.24M Estimate

Hawkins To Add Six Water Treatment Locations With Acquisitions Of Water Solutions Unlimited And Miami Products; Combined Revenue ~$1B; Expects To Add $10M In Earnings Before Interests

The most overbought stocks in the materials sector presents an opportunity to go short on these overvalued companies.
The RSI is a momentum indicator, which compares a stock&#39;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#39;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi"> RSI is above 70.</a>
Here&rsquo;s the latest list of major overbought players in this sector.
<h3>Inter &amp; Co, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/intr#NASDAQ">INTR</a>)</h3>
<ul>
<li>Inter &amp; Co posted in-line earnings for the second quarter. Jo&atilde;o Vitor Menin, CEO of Inter&amp;Co said, &ldquo;This quarter marks an inflection point in our company&rsquo;s history &ndash; it was a quarter of records, with significant achievements across many fronts. We have all cylinders firing in the right direction, showcasing Inter at its best.&rdquo; The company&rsquo;s stock has a <a href="https://www.benzinga.com/quote/INTR">52-week high of $4.63. </a>.</li>
<li>RSI Value: 70.14</li>
<li>INTR Price Action: Shares of Inter &amp; Co gained 3% to close at $4.46 on Friday.</li>
</ul>
<h3>AptarGroup, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/atr#NYSE">ATR</a>)</h3>
<ul>
<li>AptarGroup posted upbeat earnings for the second quarter. Stephan B. Tanda, Aptar President and CEO, said, &quot;Aptar delivered strong, double-digit EPS growth in the second quarter, highlighted by increased core sales in our pharma proprietary dosing and dispensing systems and the success of our beauty dispensing solutions in fragrance.&quot; The company&rsquo;s <a href="https://www.benzinga.com/quote/ATR"> stock has a 52-week high </a> of $127.68.</li>
<li>RSI Value: 77.24</li>
<li>ATR Price Action: Shares of AptarGroup gained 1.9% to close at $127.54 on Friday.</li>
</ul>
<h3>Hawkins, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hwkn#NASDAQ">HWKN</a>)</h3>
<ul>
<li>Hawkins reported better-than-expected first-quarter earnings. Patrick H. Hawkins, Chief Executive Officer and President said, &ldquo;We are pleased with our strong year-over-year performance in the first quarter, with our bottom line growing 19%. Our Water Treatment group lead the way with 19% revenue growth and operating income growth of nearly 70%.&rdquo; The company has a <a href="https://www.benzinga.com/quote/HWKN"> 52-week high </a> of $58.82.</li>
<li>RSI Value: 75.55</li>
<li>HWKN Price Action: Shares of Hawkins gained 1.3% to close at $58.40 on Friday.</li>
</ul>
&nbsp;
Read More: <a href="https://www.benzinga.com/news/earnings/23/08/34062102/investor-optimism-improves-following-powells-speech"> Investor Optimism Improves Following Powell&#39;s Speech </a>

Penny Stocks

Short Ideas

Pre-Market Outlook

INTR

Top 3 Materials Stocks That May Implode This Month

The&nbsp;trū&reg;&nbsp;Shrimp Companies, Inc. (&quot;trū Shrimp&quot;) announced today that trū Shrimp has appointed Hawkins, Inc. (&quot;Hawkins&quot;) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HWKN#NASDAQ">HWKN</a>) as the exclusive distributor of its trū&reg;&nbsp;Chitosan products into&nbsp;the United States&#39;&nbsp;pharmaceutical and medical device industries.
trū Chitosan is derived from the exoskeletons of trū Shrimp&#39;s production of consumer shrimp. Chitosan is a molecule refined from the shell of shrimp and is used for numerous pharmaceutical and medical applications. trū Shrimp is the only&nbsp;United States&nbsp;producer of chitosan that meets the strict medical specifications of the United States Pharmacopoeia &ndash; National Formulary (USP-NF) monograph.
&quot;From our first introduction, we were impressed by the quality standards set by trū Chitosan,&quot; said&nbsp;Chris Meyer, Sales Manager of Hawkins Pharmaceutical. &quot;Its trū Chitosan products meet the quality and regulatory standards our customer base demands.&quot;
&quot;From the inception of trū Shrimp, we have pursued the production of chitosan from the shells and peels of our shrimp,&quot; stated&nbsp;Michael Ziebell, President and Chief Executive Officer of trū Shrimp. &quot;trū Chitosan is the result of the vision and work of our team and partners. We are honored to have a company with the certifications and reputation of Hawkins representing trū Chitosan to the medical industry.&quot;
The shrimp are grown indoors under controlled conditions free of pollution, disease, preserving chemicals, and antibiotics. Those same conditions ensure the quality and consistency of the shell tissue raw material for the chitosan. These processes create an unprecedented chain of custody from genetics to finished chitosan which offers a precise and industry-unique Certificate of Origin critical to medical applications. &quot;Our pursuit of the world&#39;s finest chitosan starts with the world&#39;s finest shrimp,&quot; added Ziebell.
&quot;We are excited to be able to provide trū Chitosan products to our customer base,&quot; continued Meyer. &quot;Chitosan is a heavily researched biomaterial by the medical industry. Chitosan is a versatile molecule with multiple uses including topical and internal medicine as well as medical device applications.&quot;

The Trū Shrimp Companies Appoints Hawkins As Exclusive U.S. Distributor For Trū Chitosan

U.S. stocks traded mixed, with the Dow Jones gaining around 80 points on Friday. Here are some big stocks recording gains in today&rsquo;s session.
<ul>
<li>Evolv Technologies Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/evlv#NASDAQ">EVLV</a>) shares surged 24.3% to $7.24 after the company reported better-than-expected second-quarter financial results and raised FY23 revenue guidance above estimates.</li>
<li>Innodata Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/inod#NASDAQ">INOD</a>) shares climbed 23.9% to $13.22 after the company posted a narrower quarterly loss.</li>
<li>IonQ, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ionq#NYSE">IONQ</a>) gained 22% to $17.31 after the company reported second-quarter financial results.</li>
<li>Groupon, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/grpn#NASDAQ">GRPN</a>) gained 20% to $9.12. Goldman Sachs and Credit Suisse raised their price targets on the stock.</li>
<li>Bitdeer Technologies Group (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/btdr#NASDAQ">BTDR</a>) climbed 19.8% to $ 11.12 following quarterly results.</li>
<li>Tango Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tngx#NASDAQ">TNGX</a>) rose 18.8% to $7.77. HC Wainwright &amp; Co. maintained Tango Therapeutics with a Buy and raised the price target from $11 to $16.</li>
<li>Eton Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/eton#NASDAQ">ETON</a>) shares gained 17.9% to $3.0650 after posting upbeat second-quarter results.</li>
<li>ModivCare Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/modv#NASDAQ">MODV</a>) surged 16.6% to $42.31. ModivCare Director Adam Gray acquired a total of 435,893 shares at an average price of $35.74.</li>
<li>WeWork Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/we#NYSE">WE</a>) shares rose 16.4% to $0.2157 after jumping 43% on Thursday. The stock has been <a href="https://www.benzinga.com/money/most-volatile-stocks/">volatile</a> after the company recently said there was substantial doubt over its ability to stay in business.</li>
<li>Arco Platform Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/arce#NYSE">ARCE</a>) rose 15.5% to $13.81 after the company announced it signed an agreement to go private at $14 per share in cash.</li>
<li>Semler Scientific, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/smlr#NASDAQ">SMLR</a>) jumped 14.4% to $26.86 after the company reported better-than-expected second-quarter financial results.</li>
<li>Soho House &amp; Co Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/shco#NYSE">SHCO</a>) gained 14.4% to $ 7.00 after the company reported better-than-expected quarterly financial results and updated guidance.</li>
<li>CleanSpark, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/clsk#NASDAQ">CLSK</a>) rose 13.8% to $6.67 after the company reported better-than-expected third-quarter EPS results.</li>
<li>Consolidated Water Co. Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cwco#NASDAQ">CWCO</a>) gained 13.3% to $23.02. Consolidated Water reported a second-quarter revenue increase of 110% year-over-year to $44.2 million, beating estimates of $30.27 million.</li>
<li>Apellis Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/apls#NASDAQ">APLS</a>) gained 12.8% to $30.49.</li>
<li>Pagaya Technologies Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pgy#NASDAQ">PGY</a>) rose 12.5% to $2.6010 after the company reported better-than-expected second-quarter sales results.</li>
<li>Avadel Pharmaceuticals plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/avdl#NASDAQ">AVDL</a>) gained 11.4% to $14.96.</li>
<li>Erasca, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/eras#NASDAQ">ERAS</a>) surged 11.3% to $2.8950 following second-quarter results.</li>
<li>Sage Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sage#NASDAQ">SAGE</a>) rose 11% to $21.50.</li>
<li>Blend Labs, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/blnd#NYSE">BLND</a>) gained 10.5% to $1.58.</li>
<li>NextNav Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nn#NASDAQ">NN</a>) climbed 10.3% to $4.17 after the company reported second-quarter financial results.</li>
<li>Similarweb Ltd. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/smwb#NYSE">SMWB</a>) rose 10.3% to $6.67 following quarterly earnings.</li>
<li>Granite Ridge Resources, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/grnt#NYSE">GRNT</a>) gained 10.3% to $7.82 following upbeat quarterly earnings.</li>
<li>Despegar.com, Corp. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/desp#NYSE">DESP</a>) jumped 9% to $8.84. Morgan Stanley assumed Despegar.com with an Overweight rating.</li>
<li>First Foundation Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ffwm#NASDAQ">FFWM</a>) gained 8.8% to $7.85.</li>
<li>P10, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/px#NYSE">PX</a>) surged 8.6% to $12.87 following upbeat quarterly results.</li>
<li>Holley Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hlly#NYSE">HLLY</a>) gained 7.4% to $7.98 as the company reported strong earnings for the second quarter and raised its FY23 guidance.</li>
<li>Spectrum Brands Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/spb#NYSE">SPB</a>) jumped 6.2% to $79.78 following upbeat quarterly earnings.</li>
<li>Hawkins, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hwkn#NASDAQ">HWKN</a>) jumped 6% to $53.79.</li>
</ul>
&nbsp;
Read More: <a href="https://www.benzinga.com/trading-ideas/long-ideas/23/08/33746809/top-5-tech-and-telecom-stocks-that-may-explode-this-month"> Top 5 Tech And Telecom Stocks That May Explode This Month</a>

Intraday Update

Movers

APLS

ARCE

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

BLND

BTDR

CLSK

CWCO

DESP

ERAS

ETON

EVLV

FFWM

GRNT

GRPN

HLLY

INOD

IONQ

MODV

SAGE

SHCO

SMLR

SMWB

TNGX

Consolidated Water, Spectrum Brands, Arco Platform, Semler Scientific And Other Big Stocks Moving Higher On Friday

BWS Financial analyst Hamed Khorsand upgrades Hawkins (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HWKN#NASDAQ">HWKN</a>) from Neutral to Buy and announces $62 price target.

Upgrades

BWS Financial Upgrades Hawkins to Buy, Announces $62 Price Target

&nbsp;The Board of Directors of Hawkins, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HWKN#NASDAQ">HWKN</a>), at its meeting on August 2, 2023, increased its quarterly cash dividend for the second time in 2023 to&nbsp;$0.16&nbsp;per share payable September 1, 2023, to shareholders of record at the close of business on August 18, 2023. Hawkins has consistently paid out a dividend since 1985 and has increased the dividend by&nbsp;14%&nbsp;in 2023.

Dividends

Hawkins, Inc. Increases Quarterly Cash Dividend From $0.15 To $0.16/Share

Hawkins (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HWKN#NASDAQ">HWKN</a>) reported quarterly earnings of $1.12 per share which beat the analyst consensus estimate of $0.61 by 83.61 percent. This is a 19.15 percent increase over earnings of $0.94 per share from the same period last year. The company reported quarterly sales of $251.12 million which beat the analyst consensus estimate of $242.00 million by 3.77 percent. This is a 1.86 percent increase over sales of $246.54 million the same period last year.

Hawkins Q1 EPS $1.12 Beats $0.61 Estimate, Sales $251.12M Beat $242.00M Estimate

Hawkins Inc&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hwkn#NASDAQ">HWKN</a>) has finalized the buyout of EcoTech Enterprises, Inc.&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/pressreleases/23/07/g33230981/hawkins-inc-expands-water-treatment-footprint-with-acquisition-of-ecotech-enterprises-inc" style="background-image:none; background-position:initial; background-size:initial; background-repeat:initial; background-attachment:initial; background-origin:initial; background-clip:initial; margin-top:0pt; margin-bottom:0pt; color:#4a6ee0" target="_blank">for an undisclosed amount</a>.
The acquisition boosted the company&#39;s presence in the water treatment business by adding its 40th location.
EcoTech manufactures and offers water treatment chemicals to customers across Arkansas and surrounding states.
&quot;As we continue to execute on our strategy to grow our water treatment business, we believe this tuck-in acquisition will allow us to accelerate our growth in Arkansas and the surrounding region. Ecotech has built a strong business that is well-connected with the local community and we intend to maintain those connections. I would like to welcome the EcoTech team to the Hawkins organization and look forward to our continued growth together,&quot; said CEO Patrick H. Hawkins.
As of April 2, 2023, the company held cash and cash equivalent of $7.5 million and&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/pressreleases/23/05/g32454424/hawkins-inc-reports-fourth-quarter-and-fiscal-year-2023-results" style="background-image:none; background-position:initial; background-size:initial; background-repeat:initial; background-attachment:initial; background-origin:initial; background-clip:initial; margin-top:0pt; margin-bottom:0pt; color:#4a6ee0" target="_blank">net debt of $104 million</a>.
Price Action: HWKN shares are trading higher by 1.88% at $47.19&nbsp;on the last check Friday.
Now Read:&nbsp;<a href="https://www.benzinga.com/news/23/07/33222623/elon-musk-mark-zuckerberg-rivalry-heats-up-which-billionaire-pays-their-employees-more">Elon Musk, Mark Zuckerberg Rivalry Heats Up: Which Billionaire Pays Their Employees More? &nbsp;</a>
Photo: Shutterstock

Hawkins Buys EcoTech Enterprises, Boosts Water Treatment Business

Hawkins, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HWKN#NASDAQ">HWKN</a>), a leading specialty chemical and ingredients company, has added its 40th&nbsp;Water Treatment location by completing the acquisition of EcoTech Enterprises, Inc. (&quot;EcoTech&quot;). EcoTech manufactures, blends, packages and distributes water treatment chemicals for its customers throughout Arkansas and surrounding states. 
&nbsp;
&quot;As we continue to execute on our strategy to grow our water treatment business, we believe this tuck-in acquisition will allow us to accelerate our growth in Arkansas and the surrounding region. Ecotech has built a strong business that is well-connected with the local community and we intend to maintain those connections. I would like to welcome the EcoTech team to the Hawkins organization and look forward to our continued growth together,&quot; said Hawkins Chief Executive Officer Patrick H. Hawkins.

Hawkins, Inc. Expands Water Treatment Footprint With Acquisition Of EcoTech Enterprises, Inc.; No Financial Terms Disclosed

These Basic Materials stocks are trading higher:-Corteva Inc (CTVA) stock is trading at $53.83, a gain of $8.36, or 17.9%, on high volume.  Corteva Inc gets a Sentiment Score of Very Bearish from InvestorsObserver and receives an average analyst recommendation of Strong Buy with a price target of $58.70.  CTVA's next ex-di

Basic Materials Stocks on the Move Thursday: CTVA, ASPI, FQVLF, HMY, FTCO, HWKN, TSE, BHPLF

Hawkins Inc (HWKN) said after close Wednesday that it earned $0.71 per share in quarter three 2024. On the revenue line, the company reported $208.5 million, missing estimates by $12.7 million.In the same quarter a year ago, the company earned $0.51 per share on revenue of $219.2 million. The stock is down 7.62% to $61.50

Hawkins Inc Down 7.62% To $61.50 After Earnings Beat

The chemical industry's growth prospects look promising thanks to the growing demand across various sectors and the integration of technology. Therefore, it could be wise to buy fundamentally strong chemical stocks Hawkins (HWKN), Orion (OEC), and Oil-Dri Corporation of America (ODC). Read more... The chemical industry plays a crucial part in diverse applications across several end-use industries. Given the industry's steady growth prospects, investors could buy chemical stocks Hawkins, Inc. (<a href="https://stocknews.com/stock/HWKN/">HWKN</a>), Orion S.A. (<a href="https://stocknews.com/stock/OEC/">OEC</a>), and Oil-Dri Corporation of America (<a href="https://stocknews.com/stock/ODC/">ODC</a>).
The U.S. chemical industry is a $486 billion enterprise that is responsible for more than a quarter of the U.S. GDP. The industry supports the production of almost all commercial and household goods and is essential to economic growth. The US chemical industry is the <a href="https://www.cisa.gov/sites/default/files/2023-02/chemical_sector_profile_final_508_2022_0.pdf">world's second-largest chemical producer</a>, and 13% of the world's chemicals come from the US.
The global specialty chemicals market is anticipated to witness a <a href="https://www.grandviewresearch.com/industry-analysis/specialty-chemicals-market">CAGR of 5.2%</a> until 2030. This is attributed to a growing demand for construction, water treatment, and electronics chemicals, along with advancements in process technology and trade liberalization. The growth is also attributed to growing demand for pharmaceuticals, food and feed additives, and flavors and fragrances, among others.
Advancements in <a href="https://www2.deloitte.com/us/en/pages/energy-and-resources/articles/future-of-digitalization-in-the-chemical-industry.html">digital technology</a> are transforming the strategic landscape for chemical manufacturers. Producers are expected to use various digital tools to create innovative materials and streamline efficient formulations – evaluating, optimizing, and incorporating ingredient recipes and proprietary knowledge.
Consequently, the <a href="https://www.globenewswire.com/en/news-release/2023/06/06/2683143/0/en/Chemical-Industry-Forecast-2023-2032-Insights-Into-Market-Size-Growth-Rate-And-Drivers-By-The-Global-Market-Model.html">global chemical market</a> is anticipated to grow at a CAGR of 8.8% until 2032.
With these favorable trends in mind, let's delve into the fundamentals of the three best <a href="https://stocknews.com/category/chemicals/">Chemicals</a> stocks, beginning with the third choice.
Stock #3: Hawkins, Inc. (<a href="https://stocknews.com/stock/HWKN/">HWKN</a>)
HWKN operates as a specialty chemical and ingredients company in the United States. It operates through three segments: Industrial, Water Treatment, and Health and Nutrition.
HWKN's trailing-12-month asset turnover ratio of 1.46x is 114.8% higher than the industry average of 0.70x, while its trailing-12-month net income margin of 7.91% is 35.3% higher than the industry average of 5.85%.
For the fiscal third quarter that ended December 31, 2023, HWKN's sales stood at $208.50 million. Its operating income increased 21% year-over-year to $18.47 million Its net income increased 38.8% year-over-year to $14.89 million and EPS increased 38.5% year-over-year to $0.72.
Street expects revenue to be $217.5 million for the fiscal fourth quarter ending March 2024. Its EPS is expected to grow at 24% year-over-year to $0.68 for the same quarter. The company surpassed consensus EPS estimates in each of the trailing four quarters, which is impressive.
The stock has gained 45.1% over the past nine months to close the last trading session at $59.08.
HWKN's <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a> reflect its promising outlook. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, with each factor weighted to an optimal degree.
It has a C grade for Value, Growth, Quality, Stability and Sentiment. It is ranked #29 in the 84-stock <a href="https://stocknews.com/category/chemicals/">Chemicals</a> industry.
Beyond what is stated above, we've also rated HWKN for Momentum. Get all HWKN ratings <a href="https://stocknews.com/stock/HWKN/">here</a>.
Stock #2: Orion S.A. (<a href="https://stocknews.com/stock/OEC/">OEC</a>) 
OEC manufactures and sells carbon black products. It operates in two segments, Specialty Carbon Black and Rubber Carbon Black. The company offers post-treated specialty carbon black grades for coatings and printing applications; high purity carbon black grades for the fiber industry; and conductive carbon black grades for polymers, coatings, and battery electrodes.
On January 22, 2024, OEC announced it had completed upgrading its air emissions control technology at all four of its U.S. carbon black plants, the biggest sustainability-related initiative in the company's history.
The stock's trailing-12-month EBIT margin of 11.65% is 1.2% higher than the industry average of 11.511%. Its levered FCF margin of 10.08% is 127.7% higher than the 4.42% industry average.
For the fiscal third quarter that ended September 30, 2023, OEC's net sales came in at $466.20 million. Its <a href="https://www.investopedia.com/terms/a/adjusted-ebitda.asp">adjusted EBITDA</a> came in at $77.30 million. Additionally, the company's adjusted net income came in at $28.90 million, while adjusted EPS stood at $0.49.
The consensus revenue estimate of $421.69 million for the fiscal fourth quarter ending December 2023. Likewise, the consensus EPS estimate of $0.34 for the same quarter is estimated to grow 29% year-over-year to $0.34. Moreover, the company surpassed the consensus EPS estimates in each of four trailing quarters.
Shares of OEC have gained 13.3% over the past three months to close the last trading session at $22.68.
It's no surprise that OEC has an overall rating of B, which equates to Buy in our proprietary rating system.
OEC has a B grade for Value and Quality. It is ranked #19 in the same industry.
In addition to the POWR Ratings highlighted above, one can access OEC's ratings for Stability, Sentiment, Momentum, and Growth <a href="https://stocknews.com/stock/OEC/">here</a>.
Stock #1: Oil-Dri Corporation of America (<a href="https://stocknews.com/stock/ODC/">ODC</a>) 
ODC develops, manufactures, and markets sorbent products in the United States and internationally. It operates in two segments, Retail and Wholesale Products Group, and Business to Business Products Group.
For the fiscal first quarter that ended October 31, 2023, ODC's net sales increased 13.1% year-over-year to $111.44 million. Its gross profit grew 38.9% from the year-ago value to $30.99 million. Additionally, net income and net income per share grew 105.4% and 100% from the prior year's quarter to $10.74 million and $1.61, respectively.
Shares of ODC have gained 50.4% over the past nine months, closing the last trading session at $63.22.
ODC's strong fundamentals are reflected in its POWR Ratings. It has an overall rating of B, which equates to Buy in our proprietary rating system.
ODC has a B grade for Growth, Stability, and Sentiment. It is ranked #15 in the same industry.
<a href="https://stocknews.com/stock/ODC/">Click here</a> to access the additional ODC ratings (Momentum, Quality, and Value).
What To Do Next?
Discover 10 widely held stocks that our proprietary model shows have tremendous downside potential. Please make sure none of these "death trap" stocks are lurking in your portfolio:
<a href="https://report.stocknews.com/free-report/10-stocks-to-sell/?formplacement=artbotad_10sell">10 Stocks to SELL NOW! &gt;</a> 

<hr />
HWKN shares were trading at $59.41 per share on Wednesday afternoon, up $0.33 (+0.56%). Year-to-date, HWKN has declined -15.63%, versus a 4.61% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Nidhi Agarwal</h2> <img src='https:/wp-content/uploads/2023/03/Nidhi-Agarwal_Headshot-3.jpg' style="float:left; padding:5px;width:125px;">Nidhi is passionate about the capital market and wealth management, which led her to pursue a career as an investment analyst. She holds a bachelor's degree in finance and marketing and is pursuing the CFA program.

Her fundamental approach to analyzing stocks helps investors identify the best investment opportunities.<a href="https://stocknews.com/authors/?author=nidhi-agarwal">More...</a>The post <a href=https://stocknews.com/news/hwkn-oec-odc-3-underrated-chemical-stocks-with-buying-potential/>3 Underrated Chemical Stocks With Buying Potential</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Underrated Chemical Stocks With Buying Potential

Dividend Champion, Contender, And Challenger Highlights: Week Of February 11

Hawkins goes ex dividend tomorrow

Dividend Champion, Contender, And Challenger Highlights: Week Of February 25

Hawkins expands water treatment footprint with acquisition of Industrial Research Corp

Inflation doesn't seem to be moving higher, but its downward trajectory seems to have slowed to a crawl, around 3.2%, which is keeping interest rates higher than anticipated.

Tuesday Talk: Still Talk Of The Town - Inflation

Small-cap stocks should not be overlooked. These 3 small cap stocks pay dividends and have a long runway of growth.